|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

1Life Sciences Institute and Department of Cell and Developmental Biology, 2Department of Biological Chemistry, University of Michigan Medical Center, Ann Arbor, Michigan; and 3Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas
Submitted 25 August 2008 ; accepted in final form 12 January 2009
Plasma homocysteine (Hcy) is an independent risk factor for cardiovascular disease. Hcy is a nonprotein amino acid derivative that is generated from the methionine cycle, which provides the methyl group for essentially all biological methylation reactions. Although plasma Hcy levels are elevated in patients with cardiovascular disease, the mechanisms that regulate Hcy homeostasis remain poorly defined. In this study, we found that the expression of key enzymes involved in Hcy metabolism is induced in the liver in response to fasting. This induction coincides with increased expression of peroxisome proliferator-activated receptor-
coactivator (PGC)-1
, a transcriptional coactivator that regulates hepatic gluconeogenesis and mitochondrial function. PGC-1
stimulates the expression of genes involved in Hcy metabolism in cultured primary hepatocytes as well as in the liver. Adenoviral-mediated expression of PGC-1
in vivo leads to elevated plasma Hcy levels. In contrast, mice deficient in PGC-1
have lower plasma Hcy concentrations. These results define a novel role for the PGC-1
coactivator pathway in the regulation of Hcy homeostasis and suggest a potential pathogenic mechanism that contributes to hyperhomocysteinemia.
transcriptional coactivator; peroxisome proliferator-activated receptor-
coactivator 1
; homocysteine; liver metabolism; cardiovascular disease
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |